Compare ACADIA Pharmaceuticals Inc. (ACAD) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs MasTec Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.38 (market cap $5.07B), while MasTec Inc trades at $282.09 (market cap $21.90B). The key difference: MasTec Inc is far larger — about 4.3× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | MTZ | |
|---|---|---|
Market Cap | $5.07B | $21.90B |
Sector | Health | Technology |
52-Week High | $29.41 | $437.51 |
52-Week Low | $20.06 | $172.51 |
Enterprise Value | $4.19B | $24.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
MasTec (MTZ) trades at $283.76, up 5.77% over 24 hours, with a bearish technical signal but strong fundamentals. The company reported record Q2 2026 revenue of $4.374 billion, up 23% year-over-year, and raised its full-year outlook. Analyst consensus is overwhelmingly bullish with a $439.56 price target, though technical indicators show resistance near $283.
The outlook remains positive due to robust infrastructure demand, a record $21.4 billion backlog, and strategic acquisitions like The Superior Group. Risks include execution challenges in communications segments and high valuation multiples. Earnings growth and backlog execution are key catalysts for further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
